Navidea Biopharmaceuticals plans to sell an $8 million milestone payment it has received and to seek a $2.75 million equity line of credit.
The radiopharmaceutical developer said these moves will provide funding for its phase IIb (NAV3-32) and phase III (NAV3-33) trials and expand operations.